TACKLING THE OPIOID EPIDEMIC

WITH OUR NOVEL GENE THERAPY FOR CHRONIC PAIN

Chronic Pain

30% of Americans are living with some form of chronic or severe pain.

More people live with CHRONIC PAIN than CANCER, HEART DISEASE, and DIABETES, combined.

Contenido

Crisis

Contenido
Opioids

300% increase in opioid prescriptions in the last decade

Contenido
Navegatex

1 in 4 patients become addicted to opioids

Contenido
Money

More than $560B spent annually on healthcare due to pain disorders

Contenido
sad

121 Americans die every day from an opioid overdose

 

Our Approach

We have developed a gene therapy to target pain that is non-addictive, highly specific, and long-lasting.

 

Contenido

 

Our Technology

We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by utilizing a novel gene therapy to target pain. In our proof of concept, we have demonstrated our therapy increases pain tolerance and lowers pain levels. 

 

Contenido

Our Company 

Founded in 2018, Navega Therapeutics Inc. is a preclinical stage company pursuing a radically different approach to treat chronic pain and tackle the opioid epidemic. Our gene therapy platform has the advantage of being highly specific and long-lasting, which has not been achieved by small molecules thus far. Our pipeline includes different types of pain to improve the quality of life of millions of patients.

Team
 Ana Moreno

Ana Moreno

Co-founder and CEO
Ana Moreno is the co-founder and CEO of Navega Therapeutics. She is currently a PhD candidate in the Bioengineering Department at UCSD, where she spent the last four years developing the platform that enables Navega’s innovative approach.
Prashant Mali

Prashant Mali

Co-founder and Scientific Advisor
Prashant is an assistant professor in the Department of Bioengineering at the UC San Diego. Research in his laboratory lies at the interface of basic science and technology development, towards enabling gene and cell based human therapeutics.
Fernando Aleman Guillen

Fernando Aleman

CSO
Fernando obtained his PharmD degree at University of Granada and his PhD at University of Murcia. After postdoc training at UCSD and the Scripps, he leverages his pharmaceutical and industry background to provide medical oversight and strategic direction.
Tony L. Yaksh

Tony L. Yaksh

Scientific Advisor
Tony is Professor in Anesthesiology and Pharmacology at UC San Diego (1988-present). His studies (> 850 papers) provide a basis for understanding the pharmacology of pain processing, focused on spinal systems and delivery of neuraxial therapeutics.
Contenido

Contact us!

Accept | I have read and I accept the Terms and Privacy Statement.

Navega Therapeutics Inc.

Array